Literature DB >> 21289612

Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond.

Joachim Sieper1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21289612     DOI： 10.1038/nrrheum.2010.224

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?

Authors:  Martin Rudwaleit; Muhammad A Khan; Joachim Sieper
Journal:  Arthritis Rheum       Date:  2005-04

Review 2.  Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.

Authors:  Joachim Sieper; Heiner Appel; Jürgen Braun; Martin Rudwaleit
Journal:  Arthritis Rheum       Date:  2008-03

3.  Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.

Authors:  J D Carter; L R Espinoza; R D Inman; K B Sneed; L R Ricca; F B Vasey; J Valeriano; J A Stanich; C Oszust; H C Gerard; A P Hudson
Journal:  Arthritis Rheum       Date:  2010-05

4.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

5.  A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.

Authors:  Maxime Dougados; Bernard Combe; Jürgen Braun; Robert Landewé; Jean Sibilia; Alain Cantagrel; Antoine Feydy; Désirée van der Heijde; Véronique Leblanc; Isabelle Logeart
Journal:  Ann Rheum Dis       Date:  2010-05-28       Impact factor: 19.103

6.  Dickkopf-1 is a master regulator of joint remodeling.

Authors:  Danielle Diarra; Marina Stolina; Karin Polzer; Jochen Zwerina; Michael S Ominsky; Denise Dwyer; Adelheid Korb; Josef Smolen; Markus Hoffmann; Clemens Scheinecker; Desiree van der Heide; Robert Landewe; Dave Lacey; William G Richards; Georg Schett
Journal:  Nat Med       Date:  2007-01-21       Impact factor: 53.440

7.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

8.  Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

Authors:  Désirée van der Heijde; Robert Landewé; Xenofon Baraliakos; Harry Houben; Astrid van Tubergen; Paul Williamson; Weichun Xu; Daniel Baker; Neil Goldstein; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2008-10

9.  Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis.

Authors:  John D Carter; Hervé C Gérard; Luis R Espinoza; Louis R Ricca; Joanne Valeriano; Jessica Snelgrove; Cynthia Oszust; Frank B Vasey; Alan P Hudson
Journal:  Arthritis Rheum       Date:  2009-05

10.  Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints.

Authors:  S Uderhardt; D Diarra; J Katzenbeisser; J-P David; J Zwerina; W Richards; G Kronke; G Schett
Journal:  Ann Rheum Dis       Date:  2009-03-19       Impact factor: 19.103
  10 in total
  3 in total

Review 1.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

Review 2.  Juvenile spondyloarthropathies.

Authors:  R Hal Scofield; Andrea L Sestak
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

3.  Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.

Authors:  Pascal Zufferey; Jacqueline Ghosn; Fabio Becce; Adrian Ciurea; Bérengère Aubry-Rozier; Axel Finckh; Alexander K So
Journal:  Rheumatol Int       Date:  2014-07-29       Impact factor: 2.631
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.